Government Proposes Tougher Action Against Substandard Medicines to Strengthen Drug Safety

The central government has proposed stricter regulations to improve the quality and safety of medicines manufactured in India. Under the proposed changes to the Drugs Rules, 1945, authorities could immediately suspend the manufacturing licences of companies producing medicines that fail specified critical quality standards.

Immediate Suspension of Manufacturing Licences Proposed

The Union Ministry of Health and Family Welfare has proposed amendments that would allow authorities to take faster action against manufacturers whose medicines are declared Not of Standard Quality (NSQ) on specified critical parameters.

The proposal aims to strengthen regulatory oversight and prevent substandard medicines from remaining in circulation.

Stronger Action Against Quality Violations

Under the proposed framework, drug manufacturers could face quicker regulatory action when serious quality failures are identified.

The move is intended to improve accountability among pharmaceutical companies and encourage stricter quality-control practices during medicine production.

What It Means for Patients

Medicine quality is essential for safe and effective treatment. Stronger monitoring and faster action against serious manufacturing violations could help improve public confidence in medicines.

However, the proposed amendments are not yet the same as an implemented rule.

Their final provisions and implementation will depend on the government’s regulatory process.

Focus on Safer Medicines

The proposal reflects the government’s effort to strengthen India’s pharmaceutical quality-control system and improve patient safety through more effective regulation.

The post Government Proposes Tougher Action Against Substandard Medicines to Strengthen Drug Safety first appeared on newsremind.com.